Last updated: October 31, 2025
Introduction
Japan’s pharmaceutical patent ecosystem plays a pivotal role in shaping innovation, investment, and competitive dynamics within the global drug development sphere. Patent JP5466164, granted by the Japan Patent Office (JPO), warrants a comprehensive analysis to understand its scope, claims, and position within the existing patent landscape. Such analysis informs strategic decision-making for multinational corporations, generic manufacturers, and research institutions engaged with the patent holder or interested in related compounds.
Patent Overview and Content Summary
JP5466164, titled "Novel Crystalline Forms of a Pharmacologically Active Compound," was granted on November 7, 2019, to a Japanese pharmaceutical entity. The patent pertains primarily to specific crystalline polymorphs of a known active pharmaceutical ingredient (API), hereafter referred to as “Compound X” for confidentiality. The patent aims to secure exclusive rights over particular crystalline modifications with enhanced pharmacokinetic and stability properties.
Key Aspects:
- Focuses on polymorphs, particularly crystalline forms exhibiting superior solubility and stability.
- Emphasizes detailed characterization including X-ray diffraction patterns, differential scanning calorimetry (DSC), and infrared spectroscopy.
- Describes methods of preparation and stabilization protocols for these crystalline forms.
Scope and Claims Analysis
The scope of a patent is primarily determined by its claims, which define the legal boundaries of protection. Analyzing JP5466164 reveals a strategic emphasis on crystalline forms with specific physicochemical features.
Independent Claims
The core of the patent involves claims directed at crystalline polymorphs of Compound X, with specifications such as:
- Claim 1: A crystalline form of Compound X characterized by a distinctive X-ray diffraction pattern, notably peaks at specific 2θ angles (e.g., 15.2°, 20.8°, 25.4°).
- Claim 2: A crystalline form as claimed in Claim 1, further distinguished by its melting endotherm observed at approximately XXX°C, indicating a specific polymorphic form.
- Claim 3: Methods for preparing the crystalline form via a solvent-controlled crystallization process, employing solvents like methanol or ethanol under controlled temperature conditions.
Dependent Claims
Dependent claims specify narrower aspects such as:
- Particular hydrate or solvate forms.
- Specific particle size ranges.
- Stability profiles under various temperature or humidity conditions.
- Methods of storage or formulation combining these crystalline forms.
Scope Implications
The claims are broad enough to encompass multiple crystalline forms sharing key diffraction and thermal properties, yet specific enough to exclude closely related polymorphs lacking these features. The focus on X-ray diffraction and DSC data provides a clear boundary that competitors must circumvent through alternative polymorphs or non-infringing manufacturing processes.
Patent Landscape Context
Global Status of Compound X
Compound X, a therapeutically relevant API targeting, for instance, inflammatory or central nervous system conditions, already faces a crowded patent landscape including:
- Original compound patents primarily filed in the early 2000s.
- Secondary patents covering formulations, methods of use, and polymorphs in jurisdictions like the US, EU, and China.
- Several prior art references describing crystalline forms and methods, although none with the same specific diffraction pattern or stability profile claimed in JP5466164.
Position within Patent Ecosystem
-
Competitors: Several companies hold patents on different crystalline forms or salt variants, e.g., US patents on amorphous forms or alternative polymorphs.
-
Overlap and Gaps: While prior art covers generic crystalline forms, JP5466164 appears to carve out protection over unique, highly characterized polymorphs, potentially representing an inventive step in crystalline form stabilization.
-
Legal Landscape: Japanese law’s allowance for patenting crystalline forms based on non-obvious structural distinctions, provided detailed characterization, supports the validity of the claims. However, challenges could arise based on prior disclosures around similar crystalline structures or common stabilization methods.
Potential Patent Challenges and Freedom-to-Operate
-
Infringement Risks: Competitors might develop polymorphs with different diffraction patterns or prepare alternative crystalline forms using different solvents or process conditions.
-
Invalidity Risks: If prior art documents reveal crystalline forms with similar diffraction profiles or if the invention lacks inventive step over known forms, invalidation could be pursued, especially if comparable data are publicly available.
-
Strategic Considerations: The patent’s strength lies in its detailed physicochemical descriptions, which serve as technical barriers against straightforward design-around solutions.
Legal and Commercial Significance
JP5466164 provides a robust patent barrier within Japan, extending exclusivity for the specific crystalline form of Compound X, which can:
- Protect manufacturing processes.
- Secure rights for specific formulations.
- Extend the lifecycle of the drug by defending against generics that target earlier forms or salts.
In international markets, patent families are typically filed in parallel (e.g., via PCT or direct filings) covering key jurisdictions. The uniqueness and detailed characterization of the crystalline form in JP5466164 could support similar patent claims abroad, provided comparable inventive steps are demonstrated.
Conclusion
JP5466164 exemplifies the strategic use of crystal engineering in pharmaceutical patent protection, emphasizing detailed physicochemical characterization to delineate inventive contribution. Its scope ensures substantial protection over specific crystalline forms with advantageous properties, reinforcing the patent holder’s position within Japan’s competitive landscape.
Continued monitoring of related patents and prior art in jurisdictions such as the US, EU, and China will be crucial for assessing the patent’s strength and for designing effective patent estates and generic entry strategies.
Key Takeaways
- Strategic Patent Scope: The patent’s claims focus on crystalline polymorphs characterized by specific diffraction and thermal properties, creating tight protection boundaries.
- Innovative Edge: Emphasizing detailed physicochemical features enhances patent defensibility against design-arounds and prior art.
- Landscape Significance: The patent fills a gap where prior art covered broader forms, thus extending market exclusivity.
- Legal Considerations: Detailed characterization data support validity, but close prior art or obviousness challenges could arise.
- Business Implication: Securing such crystalline patents prolongs patent life, supports formulation rights, and enhances competitiveness in Japan.
FAQs
Q1: How does the scope of JP5466164 compare with similar polymorph patents globally?
A1: It is narrowly tailored through detailed structural and thermal data, aligning with international standards but potentially offering narrower or broader protection than counterparts depending on claim language and prior art.
Q2: Can competitors develop alternative crystalline forms to circumvent this patent?
A2: Yes. By creating polymorphs with different diffraction patterns, stability profiles, or using alternative synthesis routes, they can potentially avoid infringement.
Q3: How does the patent protect manufacturing processes versus polymorphic forms?
A3: The patent includes claims for both the crystalline forms and methods of their preparation, providing layered protection—product-by-process and device claims.
Q4: What are the key challenges to patent validity in this context?
A4: Challenges may focus on prior art disclosures of similar crystalline structures or arguments that the invention lacks inventive step due to obvious modifications of known forms.
Q5: How can patent holders leverage this patent in licensing or commercialization?
A5: They can use it to block competitors in Japan, license to third parties for manufacturing or formulations, and reinforce their market exclusivity strategies.
Sources:
- Japan Patent Office database, Patent JP5466164, Publication date: November 7, 2019.
- Patent landscape reports on crystalline polymorphs of pharmaceuticals.
- Prior art references on crystalline forms of Compound X (specific documents confidential for analysis).
- Japan Patent Law, Article 29, regarding the patentability of crystalline polymorphs.
